Alpha Cubed Investments LLC Maintains Position in Neurocrine Biosciences, Inc. (NBIX)

Alpha Cubed Investments LLC held its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,000 shares of the company’s stock at the end of the second quarter. Alpha Cubed Investments LLC’s holdings in Neurocrine Biosciences were worth $1,656,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Neurocrine Biosciences by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,735,965 shares of the company’s stock worth $291,666,000 after buying an additional 293,755 shares during the period. BlackRock Inc. boosted its position in shares of Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after buying an additional 4,996,784 shares in the last quarter. Janus Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock worth $188,759,000 after buying an additional 2,002,899 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of Neurocrine Biosciences by 1.5% in the first quarter. Perceptive Advisors LLC now owns 3,366,530 shares of the company’s stock worth $145,771,000 after buying an additional 50,007 shares in the last quarter. Finally, BB Biotech AG boosted its position in shares of Neurocrine Biosciences by 1.6% in the first quarter. BB Biotech AG now owns 3,201,552 shares of the company’s stock worth $138,627,000 after buying an additional 50,000 shares in the last quarter. 95.87% of the stock is owned by institutional investors.

Neurocrine Biosciences, Inc. (NBIX) opened at 52.15 on Friday. The company’s 50-day moving average price is $49.49 and its 200 day moving average price is $47.26. Neurocrine Biosciences, Inc. has a 52-week low of $37.35 and a 52-week high of $55.38. The firm’s market capitalization is $4.60 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The company had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same quarter in the prior year, the company posted ($0.46) earnings per share. Equities research analysts predict that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Alpha Cubed Investments LLC Maintains Position in Neurocrine Biosciences, Inc. (NBIX)” was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/alpha-cubed-investments-llc-has-1656000-position-in-neurocrine-biosciences-inc-nbix-updated-updated.html.

NBIX has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target (down previously from $62.00) on shares of Neurocrine Biosciences in a research report on Wednesday, May 24th. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Oppenheimer Holdings, Inc. set a $70.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, May 24th. J P Morgan Chase & Co set a $57.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $67.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have assigned a buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of “Buy” and an average target price of $68.25.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the transaction, the insider now owns 154,601 shares of the company’s stock, valued at $7,730,050. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Dimitri E. Grigoriadis sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $53.39, for a total value of $533,900.00. Following the transaction, the insider now directly owns 107,691 shares in the company, valued at approximately $5,749,622.49. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,588 shares of company stock worth $2,940,070. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply